Anil Parsram Bidkar, PhD

I am a radiopharmaceutical scientist in the Department of Radiology and Biomedical Imaging at UCSF, developing targeted molecular imaging and radioligand therapy strategies for cancer. My research focuses on antibody-based and ligand-directed theranostics that enable both noninvasive PET imaging and targeted delivery of therapeutic radionuclides, with an emphasis on alpha- and beta-emitting radiometals. I integrate radiochemistry, quantitative imaging, and translational tumor model development to evaluate new agents targeting clinically relevant cancer antigens, including CD46, PSMA, STEAP1, DLL3, and ALPPL2, across prostate cancer, pancreatic cancer, and other solid tumors. A major goal of my work is to understand and overcome mechanisms of resistance to radioligand therapy, and to develop rational combination strategies incorporating antibody-drug conjugates and other targeted therapeutics. In parallel, I am developing binder discovery platforms, including phage display-based approaches, to identify novel high-affinity targeting ligands that expand the scope of actionable cancer antigens for next-generation theranostic development.